Abbott Laboratories
ABT
$133.61
-$4.10-2.98%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.97B | 10.64B | 10.38B | 9.96B | 10.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.97B | 10.64B | 10.38B | 9.96B | 10.24B |
| Cost of Revenue | 4.97B | 4.70B | 4.52B | 4.45B | 4.50B |
| Gross Profit | 6.00B | 5.94B | 5.85B | 5.51B | 5.74B |
| SG&A Expenses | 2.74B | 2.76B | 2.78B | 2.82B | 2.54B |
| Depreciation & Amortization | 465.00M | 470.00M | 471.00M | 472.00M | 481.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.93B | 8.64B | 8.45B | 8.43B | 8.10B |
| Operating Income | 2.04B | 1.99B | 1.93B | 1.54B | 2.15B |
| Income Before Tax | 2.03B | 1.94B | 1.61B | 1.44B | 1.80B |
| Income Tax Expenses | -7.20B | 294.00M | 305.00M | 211.00M | 201.00M |
| Earnings from Continuing Operations | 9.23B | 1.65B | 1.30B | 1.23B | 1.59B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.23B | 1.65B | 1.30B | 1.23B | 1.59B |
| EBIT | 2.04B | 1.99B | 1.93B | 1.54B | 2.15B |
| EBITDA | 2.85B | 2.80B | 2.73B | 2.34B | 2.96B |
| EPS Basic | 5.27 | 0.94 | 0.74 | 0.70 | 0.91 |
| Normalized Basic EPS | 0.68 | 0.70 | 0.65 | 0.53 | 0.73 |
| EPS Diluted | 5.26 | 0.94 | 0.74 | 0.70 | 0.91 |
| Normalized Diluted EPS | 0.68 | 0.69 | 0.65 | 0.53 | 0.73 |
| Average Basic Shares Outstanding | 1.75B | 1.74B | 1.75B | 1.74B | 1.75B |
| Average Diluted Shares Outstanding | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B |
| Dividend Per Share | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 |
| Payout Ratio | 10.38% | 58.32% | 73.81% | 78.12% | 55.71% |
